ArticleNPJ breast cancer2025

Baseline cell cycle and immune profiles indicate CDK4/6 inhibitor response in metastatic HR + /HER2- breast cancer.

Stephanie L Tzetzo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.